Lipid management remains a cornerstone of cardiovascular risk reduction, with persistent evidence-practice gaps in LDL-cholesterol target attainment. The therapeutic landscape spans statins, ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, and siRNA-based PCSK9 inhibitors, offering multiple escalation pathways.
Real-world prescribing analyses reveal significant shifts: PCSK9 inhibitor use rose from 33% to 40% of lipid-lowering prescriptions between the first halves of 2023 and 2024, while statin monotherapy declined from 42% to 30%. The phase 4 AMUNDSEN trial (n=2,166 acute MI patients) is evaluating early PCSK9 inhibitor initiation pre-percutaneous coronary intervention to assess whether acute-phase LDL reduction and anti-inflammatory plaque stabilization translate into improved 12-month cardiovascular outcomes. These data challenge conventional stepwise escalation and raise questions about optimal LDL targets, treatment sequencing, and cost-effectiveness across therapy classes.
Cardiologists, endocrinologists, and primary care physicians managing dyslipidemia will benefit from peer discussion of PCSK9 inhibitor positioning, combination therapy sequencing, early acute-phase intervention evidence, and strategies to improve LDL target attainment.
How do you sequence lipid-lowering therapies, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors, in patients with high cardiovascular risk who have not achieved their LDL target? What evidence or clinical factors would lead you to consider earlier PCSK9 inhibitor initiation in the acute coronary syndrome setting, rather than following stepwise guideline-recommended escalation?
-
BRETT NILE5hStart with statins, then add zetia for cahs pay/medicare patients. add PSK9 for secondary prevention and high risk primary prevention, bempedoic acid for stating intolerant patients -
SACHINKUMAR PANCHALYesterdayusually start with a high-intensity statin, then add ezetimibe if LDL cholesterol remains above target. For patients who still do not reach goal, are statin intolerant, or are at very high cardiovascular risk, I consider bempedoic acid or a PCSK9 inhibitor based on the patient’s risk profile, LDL level, tolerability, cost, and access. In acute coronary syndrome, I would consider earlier PCSK9 inhibitor use in very high-risk patients with markedly elevated LDL or recurrent events, particularly if rapid LDL reduction is needed, while also considering the latest clinical evidence and guideline recommend
-
PETER YIPYesterdayI usually start with a statin. If not to goal and compliant with high intensity statin therapy, I add ezetimibe, then discuss adding PCSK9 therapy if still not to goal, or if patient tolerates any of the former options poorly. Seems that insurance coverage is becoming less of a barrier with time, which is promising.